Angers Cedex 2, France Clinical Trials

A listing of Angers Cedex 2, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 388 clinical trials
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

CHU d'Angers /ID# 219129
 (0.7 away) Contact site
  • 181 views
  • 29 Apr, 2021
  • +224 other locations
featured
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously treated with systemic chemotherapy.

Institut de Cancerologie de L Ouest - Site Paul Papin
 (0.7 away) Contact site
  • 6 views
  • 29 Jul, 2021
  • +83 other locations
featured
Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis is a type of bone marrow cancer that usually develops slowly and disrupts body's normal production of blood cells. It causes bone marrow scarring, leading to severe anemia that can cause weakness and fatigue. It can also cause a low number of blood-clotting cells called platelets, which increases …

CHU d'Angers /ID# 219115
 (0.7 away) Contact site
  • 32 views
  • 29 Apr, 2021
  • +148 other locations
featured
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

urinary tract cancer
Research Center
 (0.5 away) Contact site
  • 1062 views
  • 08 Dec, 2020
  • +61 other locations
featured
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Research Center (DNU)
 (0.0 away) Contact site
  • 1940 views
  • 25 Mar, 2021
  • +106 other locations
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

This study will evaluate whether adult participants with moderate to severe plaque psoriasis who have been treated with secukinumab or ixekizumab for at least 6 months and are experiencing a suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms. …

secukinumab
ixekizumab
CHU d'Angers /ID# 214430
 (0.7 away) Contact site
  • 49 views
  • 03 Jul, 2021
  • +80 other locations
Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation.

The investigators propose to evaluate premedication with Propofol compared to a control strategy including a placebo with a possible rescue treatment with ketamine to ensure pain control before LISA Procedure . Investigators hypothesize that sedation with Propofol is safe and non-inferior to placebo for the risk of Mechanical Ventilation in …

Chu Angers
 (2.7 away) Contact site
  • 2 views
  • 23 Jan, 2021
  • +14 other locations
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency. The study consists of a 6 month randomized, double blind, placebo-controlled period, followed by 1 year of …

deficiency
21-ohd
Neurocrine Clinical Site
 (0.7 away) Contact site
  • 94 views
  • 26 Jul, 2021
  • +43 other locations
Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant

This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ravulizumab in adult and adolescent participants with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). In Stage 1, an open-label, single-arm period, the dosing regimen will be confirmed. In Stage 2, participants will be randomized to receive either blinded ravulizumab …

Clinical Trial Site
 (0.7 away) Contact site
  • 0 views
  • 28 Jul, 2021
  • +49 other locations
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients

The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1A. This double-blind study will assess in parallel groups 1 dose of PXT3003 compared to Placebo in CMT1A patients treated for 15 months.

CHU d'Angers, Service de Neurologie
 (0.7 away) Contact site
  • 0 views
  • 30 Jul, 2021
  • +47 other locations